Latest Communications

19 March 2012
Nautlius Neurosciences, Inc. Announces a New Approval for CAMBIA® in the Acute Treatment of Migraine

01 March 2012
APR Applied Pharma Research ("APR") and Labtec GmbH ("Labtec") announce the European approval of Zolmitriptan Oral Dispersible Film (ODF)

18 January 2012
APR Applied Pharma Research s.a. (“APR”), Labtec GmbH (“Labtec”) and Norgine BV (“Norgine”) announce the signature of an exclusive licensing agreement under which Norgine will market and distribute Setofilm™ Ondansetron Oral Dispersible Film (“ODF”), in Europe and selected non-European countries.


oral

ORAL PHARMACEUTICALS

Project Design Planning



REGULATORY STRATEGY

The first step of the project Design Planning is the evaluation of the best Regulatory Strategy according to customer requirements. APR is able to plan and manage Scientific Advice Meetings with Health Authorities in either EU and US in order get guidance or validate regulatory and development strategies.



SELECTION OF THE BEST DELIVERY SYSTEM

On any given drug, APR is able to work through the chemical / physical / technological / pharmacokinetic characteristics of the drug candidate to determine the best option in term of finished dosage form and related development.



INVESTMENT PLAN

This is the last Step of the project Design Planning where APR is able to provide a complete Development Plan including activities, time and costs.


Search results